JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB120123

Aminoguanidine hydrochloride, NOS inhibitor

Be the first to review this product! Submit a review

|

(2 Publications)

MW 110.55 Da, Purity >98%. Irreversible inhibitor of iNOS, displaying 26-fold selectivity over nNOS. In vitro and in vivo inhibitor of the formation of glycosylation end products associated with diabetes and aging.
1 Images
Chemical Structure - Aminoguanidine hydrochloride, NOS inhibitor (AB120123)
  • Chemical Structure

Lab

Chemical Structure - Aminoguanidine hydrochloride, NOS inhibitor (AB120123)

2D chemical structure image of ab120123, Aminoguanidine hydrochloride, NOS inhibitor

Key facts

Purity

>98%

Form

Solid

form

Molecular weight

110.55 Da

Molecular formula

CH<sub>7</sub>ClN<sub>4</sub>

PubChem

16017

Nature

Synthetic

Solubility

Soluble in water to 100 mM

Biochemical name

CID 16017

Biological description

Irreversible inhibitor of iNOS, displaying 26-fold selectivity over nNOS. In vitro and in vivo inhibitor of the formation of glycosylation end products associated with diabetes and aging.

Canonical smiles

C(=N[NH3+])(N)N.[Cl-]

Isomeric smiles

C(=N[NH3+])(N)N.[Cl-]

InChi

InChI=1S/CH6N4.ClH/c2-1(3)5-4;/h4H2,(H4,2,3,5);1H

InChiKey

UBDZFAGVPPMTIT-UHFFFAOYSA-N

IUPAC Name

(diaminomethylideneamino)azanium;chloride

Properties and storage information

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
Ambient
Appropriate long-term storage conditions
Ambient
Storage information
The product can be stored for up to 12 months

Product protocols

Publications (2)

Recent publications for all applications. Explore the full list and refine your search

Diabetes care 41:2595-2602 PubMed30327363

2018

Increased Prevalence of Type 2 Diabetes-Related Complications in Combined Type 2 Diabetes and Sickle Cell Trait.

Applications

Unspecified application

Species

Unspecified reactive species

Sarah C Skinner,Mor Diaw,Vincent Pialoux,Maïmouna Ndour Mbaye,Pauline Mury,Philomène Lopez,Delphine Bousquet,Fatou Gueye,Demba Diedhiou,Philippe Joly,Céline Renoux,Djiby Sow,Saliou Diop,Brigitte Ranque,Agnès Vinet,Abdoulaye Samb,Nicolas Guillot,Philippe Connes

Experimental and therapeutic medicine 12:4107-4112 PubMed28101189

2016

Inhibition of cytoskeletal protein carbonylation may protect against oxidative damage in traumatic brain injury.

Applications

Unspecified application

Species

Unspecified reactive species

Qiusheng Zhang,Meng Zhang,Xianjian Huang,Xiaojia Liu,Weiping Li
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com